Global prevalence estimates of poststroke fatigue: A systematic review and meta-analysis

Background and purpose: Poststroke fatigue (PSF) is a common complication after stroke. However, information on the global prevalence of PSF and how this varies geographically and by population is lacking. Our aim was to examine the global prevalence of PSF and identify sources of heterogeneity in the published literature. Methods: Four medical databases (PubMed, EMBASE, PsycINFO, and Cochrane Database of Systematic Reviews) were searched from their inception to 28 February 2022. The Joanna Briggs Institute Critical Appraisal Instrument for studies reporting prevalence data (JBI) was used to assess the risk of bias (ROB) of the included studies. The primary outcome was the prevalence of PSF determined using a random-effects model. Subgroup analysis and meta-regression models were used to define the source of heterogeneity. Results: In all, 66 studies with 11,697 patients were included in this meta-analysis. The overall quality of the included studies was medium. The global pooled prevalence of PSF in stroke survivors was 46.79% (95% confidence interval (CI), 43.41–50.18%). The prevalence estimates of PSF based on the Fatigue Severity Scale (FSS), Multidimensional Fatigue Inventory-20 (MFI-20), and Fatigue Assessment Scale (FAS) were 47.44% (95% CI, 43.20–51.67%), 51.69% (95% CI, 44.54–58.83%), and 36.13% (95% CI, 23.07–49.18%), respectively. Prevalence rates of PSF were higher in females (53.19%; 95% CI, 46.46–59.92%), in hemorrhagic stroke (57.54%; 95% CI, 40.55–74.53%), in those with a college degree or higher (53.18%; 95% CI, 42.82–63.54%), and in those with unmarried or divorced status (59.78%; 95% CI, 44.72–74.83%). Conclusions: The prevalence of PSF in stroke survivors is high, affecting almost half of all stroke sufferers. PSF rates were higher with female gender, being unmarried or divorced, having a higher educational level, and being hemorrhagic compared to ischemic stroke. Trial registration: PROSPERO (CRD42021269441).